An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder

Lirio S. Covey, Mei Chen Hu, Carla A. Green, Gregory Brigham, Richard D. Hurt, Lenard Adler, Theresa Winhusen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Multisite trials, the gold standard for conducting studies in community-based settings, can mask variability across sites resulting in misrepresentation of effects in specific sites. In a placebo-controlled trial of osmotic-release oral system methylphenidate (OROS-MPH) as augmentation treatment for smokers with attention deficit hyperactivity/impulsivity disorder (ADHD), three types of sites were selected according to their clinical research specialty (ADHD, smoking cessation, and general mental health). Objective: Analysis was conducted to determine if clinical outcomes, that is, reduction in ADHD symptoms and smoking cessation rates, and the effect of treatment on these outcomes would differ by type of site. Method: A total of 255 adult smokers diagnosed with ADHD were enrolled in three clinic types: 72 in ADHD, 79 in tobacco dependence, and 104 in the mental health clinics. Results: The three site-types were similar in demographic characteristics, smoking history, baseline level of ADHD symptoms, and history of psychiatric illness. Site-type but not a site-type by treatment interaction predicted prolonged smoking abstinence. A significant three-way interaction of site-type, treatment, and time-predicted improvement in ADHD symptoms. Moderate to strong effects of OROS-MPH relative to placebo were observed in the mental health and the ADHD clinics; a weak effect was observed in the tobacco dependence clinics. Conclusion: OROS-MPH benefit varied by site for reducing ADHD symptoms but not for improving smoking abstinence. Scientific Significance: Assessment of site-type effects can indicate the generalizability of findings from multisite trials and should be routinely incorporated in the design of multisite trials.

Original languageEnglish (US)
Pages (from-to)392-399
Number of pages8
JournalAmerican Journal of Drug and Alcohol Abuse
Volume37
Issue number5
DOIs
StatePublished - Sep 2011

Fingerprint

Methylphenidate
Impulsive Behavior
Attention Deficit Disorder with Hyperactivity
Tobacco Use Disorder
Mental Health
Smoking
Smoking Cessation
Placebos
Masks
Psychiatry
Therapeutics
History
Demography

Keywords

  • Multisite trials
  • OROS-methylphenidate
  • Site effects
  • Smokers with ADHD

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder. / Covey, Lirio S.; Hu, Mei Chen; Green, Carla A.; Brigham, Gregory; Hurt, Richard D.; Adler, Lenard; Winhusen, Theresa.

In: American Journal of Drug and Alcohol Abuse, Vol. 37, No. 5, 09.2011, p. 392-399.

Research output: Contribution to journalArticle

Covey, Lirio S. ; Hu, Mei Chen ; Green, Carla A. ; Brigham, Gregory ; Hurt, Richard D. ; Adler, Lenard ; Winhusen, Theresa. / An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder. In: American Journal of Drug and Alcohol Abuse. 2011 ; Vol. 37, No. 5. pp. 392-399.
@article{c041273f000f43349820a012803b07b5,
title = "An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder",
abstract = "Background: Multisite trials, the gold standard for conducting studies in community-based settings, can mask variability across sites resulting in misrepresentation of effects in specific sites. In a placebo-controlled trial of osmotic-release oral system methylphenidate (OROS-MPH) as augmentation treatment for smokers with attention deficit hyperactivity/impulsivity disorder (ADHD), three types of sites were selected according to their clinical research specialty (ADHD, smoking cessation, and general mental health). Objective: Analysis was conducted to determine if clinical outcomes, that is, reduction in ADHD symptoms and smoking cessation rates, and the effect of treatment on these outcomes would differ by type of site. Method: A total of 255 adult smokers diagnosed with ADHD were enrolled in three clinic types: 72 in ADHD, 79 in tobacco dependence, and 104 in the mental health clinics. Results: The three site-types were similar in demographic characteristics, smoking history, baseline level of ADHD symptoms, and history of psychiatric illness. Site-type but not a site-type by treatment interaction predicted prolonged smoking abstinence. A significant three-way interaction of site-type, treatment, and time-predicted improvement in ADHD symptoms. Moderate to strong effects of OROS-MPH relative to placebo were observed in the mental health and the ADHD clinics; a weak effect was observed in the tobacco dependence clinics. Conclusion: OROS-MPH benefit varied by site for reducing ADHD symptoms but not for improving smoking abstinence. Scientific Significance: Assessment of site-type effects can indicate the generalizability of findings from multisite trials and should be routinely incorporated in the design of multisite trials.",
keywords = "Multisite trials, OROS-methylphenidate, Site effects, Smokers with ADHD",
author = "Covey, {Lirio S.} and Hu, {Mei Chen} and Green, {Carla A.} and Gregory Brigham and Hurt, {Richard D.} and Lenard Adler and Theresa Winhusen",
year = "2011",
month = "9",
doi = "10.3109/00952990.2011.596979",
language = "English (US)",
volume = "37",
pages = "392--399",
journal = "American Journal of Drug and Alcohol Abuse",
issn = "0095-2990",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder

AU - Covey, Lirio S.

AU - Hu, Mei Chen

AU - Green, Carla A.

AU - Brigham, Gregory

AU - Hurt, Richard D.

AU - Adler, Lenard

AU - Winhusen, Theresa

PY - 2011/9

Y1 - 2011/9

N2 - Background: Multisite trials, the gold standard for conducting studies in community-based settings, can mask variability across sites resulting in misrepresentation of effects in specific sites. In a placebo-controlled trial of osmotic-release oral system methylphenidate (OROS-MPH) as augmentation treatment for smokers with attention deficit hyperactivity/impulsivity disorder (ADHD), three types of sites were selected according to their clinical research specialty (ADHD, smoking cessation, and general mental health). Objective: Analysis was conducted to determine if clinical outcomes, that is, reduction in ADHD symptoms and smoking cessation rates, and the effect of treatment on these outcomes would differ by type of site. Method: A total of 255 adult smokers diagnosed with ADHD were enrolled in three clinic types: 72 in ADHD, 79 in tobacco dependence, and 104 in the mental health clinics. Results: The three site-types were similar in demographic characteristics, smoking history, baseline level of ADHD symptoms, and history of psychiatric illness. Site-type but not a site-type by treatment interaction predicted prolonged smoking abstinence. A significant three-way interaction of site-type, treatment, and time-predicted improvement in ADHD symptoms. Moderate to strong effects of OROS-MPH relative to placebo were observed in the mental health and the ADHD clinics; a weak effect was observed in the tobacco dependence clinics. Conclusion: OROS-MPH benefit varied by site for reducing ADHD symptoms but not for improving smoking abstinence. Scientific Significance: Assessment of site-type effects can indicate the generalizability of findings from multisite trials and should be routinely incorporated in the design of multisite trials.

AB - Background: Multisite trials, the gold standard for conducting studies in community-based settings, can mask variability across sites resulting in misrepresentation of effects in specific sites. In a placebo-controlled trial of osmotic-release oral system methylphenidate (OROS-MPH) as augmentation treatment for smokers with attention deficit hyperactivity/impulsivity disorder (ADHD), three types of sites were selected according to their clinical research specialty (ADHD, smoking cessation, and general mental health). Objective: Analysis was conducted to determine if clinical outcomes, that is, reduction in ADHD symptoms and smoking cessation rates, and the effect of treatment on these outcomes would differ by type of site. Method: A total of 255 adult smokers diagnosed with ADHD were enrolled in three clinic types: 72 in ADHD, 79 in tobacco dependence, and 104 in the mental health clinics. Results: The three site-types were similar in demographic characteristics, smoking history, baseline level of ADHD symptoms, and history of psychiatric illness. Site-type but not a site-type by treatment interaction predicted prolonged smoking abstinence. A significant three-way interaction of site-type, treatment, and time-predicted improvement in ADHD symptoms. Moderate to strong effects of OROS-MPH relative to placebo were observed in the mental health and the ADHD clinics; a weak effect was observed in the tobacco dependence clinics. Conclusion: OROS-MPH benefit varied by site for reducing ADHD symptoms but not for improving smoking abstinence. Scientific Significance: Assessment of site-type effects can indicate the generalizability of findings from multisite trials and should be routinely incorporated in the design of multisite trials.

KW - Multisite trials

KW - OROS-methylphenidate

KW - Site effects

KW - Smokers with ADHD

UR - http://www.scopus.com/inward/record.url?scp=80052240544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052240544&partnerID=8YFLogxK

U2 - 10.3109/00952990.2011.596979

DO - 10.3109/00952990.2011.596979

M3 - Article

C2 - 21854282

AN - SCOPUS:80052240544

VL - 37

SP - 392

EP - 399

JO - American Journal of Drug and Alcohol Abuse

JF - American Journal of Drug and Alcohol Abuse

SN - 0095-2990

IS - 5

ER -